Why Would a Doctor Take a Biopsy During an Endoscopy?

Doctors take biopsies during endoscopy because many serious gastrointestinal conditions are invisible to the naked eye. Even when the lining of your esophagus, stomach, or intestine looks perfectly healthy through the camera, the tissue itself can harbor inflammation, infection, or early cellular changes that only a microscope can reveal. Sometimes the reason is straightforward: the doctor sees something abnormal and wants to know what it is. Other times, the biopsy is taken precisely because the tissue looks normal, and the diagnosis depends on finding something hidden beneath the surface.

Checking Tissue That Looks Suspicious

The most intuitive reason for a biopsy is that your doctor spots something during the procedure that warrants a closer look. This includes ulcers, polyps, thickened folds, discolored patches, or any mass that seems out of place. A visual impression alone is not enough to distinguish a benign ulcer from an early cancer, or an innocent polyp from one with pre-cancerous changes.

Gastric ulcers are a good example. Most stomach ulcers are caused by Helicobacter pylori infection or anti-inflammatory medications and will heal on their own with treatment. But a small percentage turn out to be cancerous. In one controlled study of over 500 patients, biopsying the margins and base of gastric ulcers detected gastric cancer at roughly four times the rate of biopsying only the margins, and the difference was statistically meaningful.¹ Doctors biopsy ulcers not because they think every one is cancer, but because missing the rare one that is can have devastating consequences.

Polyps present a similar challenge. During a colonoscopy (a type of lower endoscopy) or an upper endoscopy, polyps are often removed entirely and sent for analysis. But some lesions look almost identical through the scope yet behave very differently under the microscope. Sessile serrated adenomas, for instance, can look like ordinary hyperplastic polyps but carry real potential to develop into colorectal cancer.² Narrow-band imaging helps somewhat, but the definitive answer still comes from a pathologist examining the tissue.³

Lumps that sit underneath the lining of the GI tract, called subepithelial tumors, pose an even trickier problem. Standard biopsies grab only surface tissue and can miss them entirely. In those cases, doctors may use endoscopic ultrasound to guide a needle deeper into the wall to get an adequate sample. Recent guidelines recommend deciding when to do this based on tumor size and whether the ultrasound shows worrisome features.⁴

Surveillance for Barrett’s Esophagus

Barrett’s esophagus is a condition where chronic acid reflux causes the lining of the lower esophagus to change from its normal type to something that resembles the intestinal lining. On its own, Barrett’s is not cancer. But it raises the risk of developing esophageal adenocarcinoma, and the only reliable way to monitor that risk is through repeated biopsies taken during scheduled surveillance endoscopies.

The standard approach is called the Seattle protocol. Your doctor examines the Barrett’s segment carefully, takes targeted biopsies of anything that looks abnormal, and then takes additional random biopsies from all four quadrants of the esophagus at regular intervals along the affected area. The American Gastroenterological Association recommends these four-quadrant biopsies every one to two centimeters. The reason for such thorough sampling is that pre-cancerous changes, known as dysplasia, are patchy and easy to miss. Pooled data show that following the Seattle protocol detects dysplasia at a dramatically higher rate compared with less structured approaches.⁵ European guidelines similarly recommend at least four-quadrant biopsies for every two centimeters of Barrett’s length, along with careful photodocumentation and a minimum inspection time per centimeter.⁶

Despite being the gold standard, the Seattle protocol is time-consuming and doesn’t catch everything. Sampling error remains a real problem, and adherence tends to drop with longer Barrett’s segments.⁷ Newer imaging technologies are being developed to supplement or eventually replace random biopsies, but for now, tissue sampling remains the backbone of Barrett’s surveillance.

Detecting Infections and Pre-cancerous Stomach Changes

Helicobacter pylori is one of the most common reasons for biopsying the stomach. This bacterium infects roughly half the world’s population and is a leading cause of gastritis, peptic ulcers, and gastric cancer. A rapid urease test performed on a biopsy sample during the procedure can give results in minutes. For a thorough assessment, guidelines recommend taking samples from specific locations in the stomach: the lesser and greater curvatures of both the mid-antrum and middle body.⁸ Taking biopsies from multiple sites helps the doctor not only detect the infection but also assess whether it has caused atrophic changes in the stomach lining.

Related to this, doctors biopsy the stomach to check for gastric intestinal metaplasia, a condition where stomach cells start to resemble intestinal cells. This transformation is considered a pre-cancerous change and is typically diagnosed by endoscopy with biopsy.⁹ The degree and extent of metaplasia help determine how closely you need to be monitored afterward. Narrow-band imaging, an enhanced visualization mode available on many modern endoscopes, can help identify areas of metaplasia during the procedure, but biopsies are still recommended to confirm the diagnosis and grade its severity.¹⁰

When the Endoscopy Looks Normal but Symptoms Don’t Stop

Some of the most important reasons for biopsying during endoscopy have nothing to do with what the doctor can see through the camera. Several conditions cause real, ongoing symptoms while the GI lining appears completely normal on visual inspection. Skipping the biopsy in those situations means missing the diagnosis entirely.

Celiac disease is the classic example. People with celiac disease have an immune reaction to gluten that damages the lining of the small intestine, specifically the duodenum. But the damage can be subtle enough that the tissue looks unremarkable through the scope. Diagnosing celiac disease requires taking small-intestine biopsies and examining them under a microscope for characteristic damage to the villi. Adding a biopsy from the duodenal bulb, the very beginning of the small intestine, increases the diagnostic yield by about five percent overall and by about eight percent in adults.¹¹ Despite this, biopsy rates during upper endoscopy vary widely depending on the doctor. Duodenal biopsies are taken most frequently when the patient presents with diarrhea or weight loss, but are performed in only about 60 percent of procedures done for anemia or iron deficiency, even though those are also recognized signs of celiac disease.¹²

Eosinophilic esophagitis is another condition where biopsies are essential. People with this immune-driven disorder experience trouble swallowing, food getting stuck, or vomiting, and the esophagus may show rings or furrows on inspection, or it may look entirely normal. The diagnosis requires finding a specific threshold of eosinophils, a type of white blood cell, in the esophageal tissue.¹³ Without a biopsy, the condition goes undiagnosed.

Microscopic colitis follows the same pattern on the lower end of the GI tract. Patients have chronic watery diarrhea but a completely normal-looking colon on colonoscopy. The diagnosis only emerges when biopsies reveal characteristic inflammatory patterns, such as increased lymphocytes in the lining or a thickened collagen band beneath the surface.¹⁴ If your doctor biopsies a colon that looks perfectly normal, this is often what they’re looking for.

Biopsies in Transplant and Immunocompromised Patients

People who have undergone bone marrow transplants face a specific complication called graft-versus-host disease, where the donated immune cells attack the recipient’s own tissues, including the GI tract. Diagnosing this condition quickly matters because treatment decisions hinge on confirming it. Endoscopy with biopsy is the standard approach, though the best site to biopsy depends on the patient’s symptoms.

Both the stomach and duodenum can be evaluated, and the gross appearance of the mucosa combined with the biopsy results are complementary, meaning one can catch what the other misses.¹⁵ However, when researchers compared biopsy sites head to head, rectosigmoid biopsies had the highest sensitivity for diagnosing GI graft-versus-host disease, at about 96 percent, compared with roughly 73 percent for gastric biopsies and 79 percent for duodenal ones. The rectosigmoid biopsies maintained that advantage regardless of whether the patient’s main symptoms were diarrhea or nausea and vomiting.¹⁶

Immunocompromised patients more broadly, including those on immunosuppressive medications for organ transplants or autoimmune diseases, may also need biopsies to diagnose opportunistic infections of the GI tract, such as cytomegalovirus or fungal infections, that can cause ulcers indistinguishable from other causes without tissue analysis.

What Happens to Biopsy Tissue After Collection

Once the tiny tissue samples are snipped from the GI wall, they are placed into preservative and sent to a pathology lab. A pathologist processes the tissue into thin slices, stains them, and examines them under a microscope. This analysis can reveal everything from the type of inflammation present to whether cells have begun to look abnormal in ways that suggest cancer or a pre-cancerous state.

Increasingly, biopsy samples serve a second purpose beyond traditional microscopic analysis. In patients who already have or are suspected of having GI cancer, the tissue is used for molecular and biomarker testing to guide treatment. Endoscopic biopsies are now described as the gold standard for diagnosing gastrointestinal carcinoma, and reliable molecular testing on these small samples appears achievable when enough high-quality tissue is collected.¹⁷ The shift toward biomarker-based precision oncology in GI cancers has made it even more important that endoscopists collect adequate, representative samples.¹⁸

When ultrasound-guided needle biopsies are needed, the method of tissue collection matters too. Fine needle biopsy, which retrieves a small core of tissue, has been shown to provide better specimen quality and higher diagnostic accuracy than fine needle aspiration, which draws out individual cells. A meta-analysis of randomized controlled trials found that fine needle biopsy also required fewer passes of the needle.¹⁹

How Safe Is a Biopsy During Endoscopy?

Biopsies taken during endoscopy are among the lowest-risk procedures in medicine. The tissue samples are tiny, and the instruments are designed to minimize trauma. Bleeding at the biopsy site is the primary concern, but it is rarely clinically significant. In a large prospective study of nearly 3,800 patients, post-biopsy bleeding occurred in only about 0.15 percent of cases.²⁰

A common worry for patients is whether they need to stop blood thinners before the procedure. The evidence on this is reassuring. Multiple studies have found that continuing antithrombotic medications, including antiplatelet drugs and anticoagulants at therapeutic levels, does not meaningfully increase the risk of bleeding after a standard endoscopic biopsy.²¹ ²² This is one reason most guidelines classify a standard biopsy as a “low-risk” procedure for bleeding and do not require stopping blood-thinning medications beforehand. If your doctor is planning a more extensive intervention, like removing a large polyp, the bleeding calculus changes, but for routine biopsies, the risk is very small.

Getting Your Results

After a biopsy, tissue processing and pathologist review typically take a few business days to a couple of weeks, depending on the tests ordered and the lab’s workload. How quickly you hear from your doctor and how the results are communicated varies considerably.

If the doctor saw something during the procedure that looked clearly benign, like a small polyp, you may get preliminary reassurance right after the procedure. But the final answer waits for the pathology report. Studies of how gastroenterologists communicate biopsy results have revealed some inconsistency. In one survey-based study, the vast majority of endoscopists said they would immediately reassure a patient about a small, benign-appearing polyp, but fewer would offer the same reassurance for a larger one. When pathology results came back, most doctors said they would phone a patient to report benign findings, but far fewer said they would phone to relay a finding of dysplasia.²³ That counterintuitive gap, where potentially worse news is communicated less directly, is worth knowing about. If you’ve had a biopsy taken and haven’t heard back, calling the office is always reasonable. Do not assume no news is good news.

Optical Biopsy and the Future of Tissue Diagnosis

Researchers are developing a suite of technologies collectively called “optical biopsy,” which aim to provide instant tissue-level information during the endoscopy itself, without removing any tissue. These methods use the properties of light to analyze the lining of the GI tract in real time. Techniques under investigation include fluorescence endoscopy, optical coherence tomography, and confocal microendoscopy, each of which offers higher resolution or different types of contrast than a standard endoscopic image.²⁴ Some of these provide biochemical and molecular information about the tissue without any physical sampling at all.

Proteomic analysis of biopsy samples is also advancing. In inflammatory bowel disease, for instance, mass spectrometry techniques applied to biopsy tissue can identify protein patterns that help distinguish ulcerative colitis from Crohn’s disease in cases where standard pathology is inconclusive.²⁵ This kind of analysis extracts more diagnostic information from the same small piece of tissue that would have been taken anyway. For now, conventional biopsies remain indispensable. But the gap between what the camera can see and what the microscope can find is slowly narrowing, and the biopsy of the future may involve light rather than forceps.